Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.12M | 51.02M | 50.32M | 50.57M | 50.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.12M | 51.02M | 50.32M | 50.57M | 50.52M |
| Cost of Revenue | 47.05M | 46.60M | 46.43M | 46.98M | 47.17M |
| Gross Profit | 5.07M | 4.42M | 3.88M | 3.59M | 3.35M |
| SG&A Expenses | 3.63M | 3.63M | 3.63M | 3.66M | 3.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.68M | 50.22M | 50.07M | 50.64M | 50.90M |
| Operating Income | 1.45M | 795.00K | 251.00K | -72.00K | -383.00K |
| Income Before Tax | 1.46M | 818.00K | 268.00K | -63.00K | -369.00K |
| Income Tax Expenses | 527.00K | 388.00K | 156.00K | 53.00K | 16.00K |
| Earnings from Continuing Operations | 0.93 | 0.43 | 0.11 | -0.12 | -0.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 928.00K | 430.00K | 112.00K | -116.00K | -385.00K |
| EBIT | 1.45M | 795.00K | 251.00K | -72.00K | -383.00K |
| EBITDA | 1.78M | 1.13M | 570.00K | 244.00K | -58.00K |
| EPS Basic | 0.03 | 0.01 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.03 | 0.02 | 0.01 | 0.00 | -0.01 |
| EPS Diluted | 0.03 | 0.01 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.03 | 0.02 | 0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 120.47M | 120.40M | 120.26M | 120.11M | 119.96M |
| Average Diluted Shares Outstanding | 123.42M | 122.22M | 121.53M | 122.20M | 122.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
